A Hidden Brain Network May Be the Key to Better Parkinson's Treatment—Here's What Scientists Found

Scientists have identified a specific brain network that appears to be the root cause of Parkinson's disease, and targeting it with non-invasive brain stimulation produced more than twice the symptom improvement seen with standard treatments. An international research team led by China's Changping Laboratory and Washington University School of Medicine discovered that a network called the somato-cognitive action network (SCAN) becomes abnormally overconnected in people with Parkinson's, disrupting not just movement but also thinking, sleep, and other bodily functions.

The findings, published in Nature in February 2026, challenge decades of thinking about Parkinson's disease and suggest a new era of more precise, targeted treatments may be on the horizon. "This work demonstrates that Parkinson's is a SCAN disorder, and the data strongly suggest that if you target the SCAN in a personalized, precise manner you can treat Parkinson's more successfully than was previously possible," said Dr. Nico U. Dosenbach, the David M. and Tracy S. Holtzman Professor of Neurology at Washington University School of Medicine.

What Is SCAN and Why Does It Matter for Parkinson's?

The SCAN is a brain network located within the motor cortex, the area responsible for controlling body movements. Its primary job is to translate planned actions into physical motion and then monitor how those actions unfold. Dr. Dosenbach first described this network in Nature in 2023, but the new research reveals its critical role in Parkinson's disease.

Parkinson's disease affects far more than movement alone. It influences digestion, sleep, motivation, and thinking—symptoms that have long puzzled researchers focused primarily on the basal ganglia, the brain region controlling muscle movements. The discovery that SCAN dysfunction explains this broader range of symptoms represents a significant shift in understanding the disease. "For decades, Parkinson's has been primarily associated with motor deficits and the basal ganglia," explained Dr. Hesheng Liu, a senior author of the study. "Our work shows that the disease is rooted in a much broader network dysfunction. The SCAN is hyperconnected to key regions associated with Parkinson's disease, and this abnormal wiring disrupts not only movement but also related cognitive and bodily functions".

How Did Researchers Discover This Brain Network Connection?

To test whether SCAN disruption could explain Parkinson's symptoms and serve as a treatment target, Liu's team analyzed brain imaging data from more than 800 participants across multiple research centers in the United States and China. The group included people with Parkinson's disease receiving deep brain stimulation (DBS) or non-invasive therapies such as transcranial magnetic stimulation, focused ultrasound stimulation, and medications. Healthy volunteers and individuals with other movement disorders were also included for comparison.

The analysis revealed that Parkinson's disease is marked by excessive connectivity between the SCAN and the subcortex, a brain region involved in emotion, memory, and motor control. Across all four therapies examined in the study, treatments worked best when they reduced this overconnection and restored a more balanced relationship between these regions.

What Results Did Precision SCAN-Targeted Treatment Produce?

Building on these insights, the researchers developed a precision treatment system designed to target the SCAN without surgery and with millimeter-level accuracy. The approach uses transcranial magnetic stimulation, which delivers magnetic pulses to the brain through a device placed on the head. In a clinical trial, 18 patients who received SCAN-targeted stimulation showed a 56% response rate after two weeks. By comparison, only 22% of 18 patients who received stimulation to nearby brain regions improved, representing a 2.5-fold increase in effectiveness.

This dramatic difference suggests that precision targeting of the right brain network matters far more than simply applying stimulation to the general area. The results offer hope for earlier intervention, since non-invasive treatments could potentially be used much earlier than invasive deep brain stimulation, which requires brain surgery.

How Does This Compare to Current Parkinson's Treatments?

Current treatment options for Parkinson's disease include long-term medications and invasive deep brain stimulation (DBS), which can reduce symptoms but do not stop the disease from advancing or offer a cure. Meanwhile, adaptive deep brain stimulation (aDBS), which adjusts stimulation based on brain activity patterns, has shown promise in recent research. In one study, adaptive DBS yielded approximately 35% greater motor improvement than conventional DBS, with gait showing the most consistent benefits.

However, adaptive DBS still requires brain surgery and implantation of a neurostimulator device. The new SCAN-targeted approach using non-invasive transcranial magnetic stimulation could potentially offer similar or better benefits without surgical risks, making it accessible to patients earlier in their disease course.

Steps to Understanding Your Parkinson's Treatment Options

• Conventional Medications: Long-term pharmaceutical treatments that help manage symptoms but do not stop disease progression, often used as a first-line approach.
• Non-Invasive Brain Stimulation: Transcranial magnetic stimulation and focused ultrasound deliver energy to targeted brain regions without surgery, potentially offering earlier intervention opportunities.
• Invasive Deep Brain Stimulation: Surgical implantation of a neurostimulator device that delivers electrical pulses to specific brain regions, either conventional or adaptive based on brain activity patterns.
• Precision Network Targeting: Emerging approaches that focus on specific brain networks like SCAN rather than broad brain regions, showing significantly higher response rates in early trials.

What's Next for Parkinson's Treatment?

Dr. Dosenbach plans to launch clinical trials with Turing Medical, a Washington University School of Medicine startup he co-founded. These studies will test a non-invasive therapy that uses surface electrode strips placed over SCAN regions to address gait problems in people with Parkinson's disease. He also intends to explore low-intensity focused ultrasound as another non-invasive method for altering SCAN activity using acoustic energy.

The discovery that Parkinson's is fundamentally a SCAN disorder opens the door to more effective treatments and potentially earlier intervention. "With non-invasive treatments, we could start treating with neuromodulation much earlier than is currently done with DBS because they don't require brain surgery," Dr. Dosenbach noted. More foundational research is still needed to understand how different parts of the SCAN contribute to specific Parkinson's symptoms, but the initial results suggest a major shift in how the disease will be diagnosed and treated in the coming years.